FARES-II Trial: PCC Outperforms Frozen Plasma in Managing Coagulopathic Bleeding During Cardiac Surgery In the FARES-II trial, researchers investigated whether Prothrombin Complex Concentrate (PCC) could offer superior outcomes compared to frozen plasma for patients undergoing cardiac surgery who develop coagulopathic … Read More
Blog
Right Heart Catheterization: A Quick Interpretation Guide
Right Heart Catheterization (RHC) is a critical tool for diagnosing and managing various cardiovascular and pulmonary conditions. This invasive hemodynamic assessment provides real-time insight into the function and pressures of the right heart, pulmonary arteries, and left heart indirectly via … Read More
Altshock-2 Trial: IABP in Cardiogenic Shock
Altshock-2 Trial: Evaluating Early IABP Support in Cardiogenic Shock The Altshock-2 trial is a multicenter, prospective study designed to evaluate the efficacy of early intra-aortic balloon pump (IABP) support in patients with heart failure-related cardiogenic shock (HF-CS). This trial aimed … Read More
ASSET-IT Trial: Early Tirofiban Infusion in Stroke
The 2025 ASSET-IT trial investigated whether early intravenous infusion of tirofiban, an antiplatelet agent, following intravenous thrombolysis could improve outcomes in patients with acute noncardioembolic ischemic stroke who are not eligible for thrombectomy. This phase 3, double-blind, randomized, placebo-controlled study … Read More
E3 Trial: Do e-Cigarettes Help Smokers Quit?
Published in JACC Advances, June 2025 The E3 Trial evaluated whether short-term use of nicotine or non-nicotine e-cigarettes, combined with counseling, improves smoking abstinence at 1 year. This multicenter, randomized controlled trial adds critical insight into smoking cessation strategies. 🧑⚕️ … Read More
Advance-HTN Trial: Lorundrostat in Uncontrolled Hypertension
Hypertension remains a major global health issue, particularly for patients whose blood pressure remains uncontrolled despite multiple medications. The Advance-HTN trial, presented at ACC.25 in Chicago in 2025, provides compelling evidence for the use of lorundrostat, a novel aldosterone synthase … Read More
DapaTAVI Trial: Dapagliflozin in TAVR
The year 2025 brought several influential cardiovascular studies to light, and among the most promising was the DapaTAVI trial. This randomized, open-label trial explored the impact of dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, in a population often seen as high-risk … Read More
WARRIOR Trial: Women’s Ischemia Trial, Treating Non-Obstructive Coronary Artery Disease
In the ever-evolving landscape of cardiovascular research, the WARRIOR trial—short for Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD—has emerged as a pivotal investigation into how best to treat women with ischemia and no obstructive coronary artery disease (INOCA). … Read More
API-CAT Trial: Evaluating Low-Dose Apixaban for Cancer-Associated Thrombosis
API-CAT Trial: Evaluating Low-Dose Apixaban for Cancer-Associated Thrombosis Introduction The API-CAT trial is a groundbreaking study designed to evaluate whether a reduced dose of apixaban (2.5 mg twice daily) is as effective as the standard full-dose regimen (5 mg twice … Read More
BASIL-3 Trial: Evaluating Endovascular Strategies in Severe Leg Ischaemia
Staying up to date with landmark clinical trials is essential for evidence-based patient care, especially in fields like vascular surgery and interventional cardiology. The recently published BASIL-3 trial sheds light on the best endovascular approach for patients with chronic limb-threatening … Read More